Cargando…

The nature of relapse in schizophrenia

BACKGROUND: Multiple relapses characterise the course of illness in most patients with schizophrenia, yet the nature of these episodes has not been extensively researched and clinicians may not always be aware of important implications. METHODS: We critically review selected literature regarding the...

Descripción completa

Detalles Bibliográficos
Autores principales: Emsley, Robin, Chiliza, Bonginkosi, Asmal, Laila, Harvey, Brian H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3599855/
https://www.ncbi.nlm.nih.gov/pubmed/23394123
http://dx.doi.org/10.1186/1471-244X-13-50
_version_ 1782475546096041984
author Emsley, Robin
Chiliza, Bonginkosi
Asmal, Laila
Harvey, Brian H
author_facet Emsley, Robin
Chiliza, Bonginkosi
Asmal, Laila
Harvey, Brian H
author_sort Emsley, Robin
collection PubMed
description BACKGROUND: Multiple relapses characterise the course of illness in most patients with schizophrenia, yet the nature of these episodes has not been extensively researched and clinicians may not always be aware of important implications. METHODS: We critically review selected literature regarding the nature and underlying neurobiology of relapse. RESULTS: Relapse rates are very high when treatment is discontinued, even after a single psychotic episode; a longer treatment period prior to discontinuation does not reduce the risk of relapse; many patients relapse soon after treatment reduction and discontinuation; transition from remission to relapse may be abrupt and with few or no early warning signs; once illness recurrence occurs symptoms rapidly return to levels similar to the initial psychotic episode; while most patients respond promptly to re-introduction of antipsychotic treatment after relapse, the response time is variable and notably, treatment failure appears to emerge in about 1 in 6 patients. These observations are consistent with contemporary thinking on the dopamine hypothesis, including the aberrant salience hypothesis. CONCLUSIONS: Given the difficulties in identifying those at risk of relapse, the ineffectiveness of rescue medications in preventing full-blown psychotic recurrence and the potentially serious consequences, adherence and other factors predisposing to relapse should be a major focus of attention in managing schizophrenia. The place of antipsychotic treatment discontinuation in clinical practice and in placebo-controlled clinical trials needs to be carefully reconsidered.
format Online
Article
Text
id pubmed-3599855
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35998552013-03-17 The nature of relapse in schizophrenia Emsley, Robin Chiliza, Bonginkosi Asmal, Laila Harvey, Brian H BMC Psychiatry Review BACKGROUND: Multiple relapses characterise the course of illness in most patients with schizophrenia, yet the nature of these episodes has not been extensively researched and clinicians may not always be aware of important implications. METHODS: We critically review selected literature regarding the nature and underlying neurobiology of relapse. RESULTS: Relapse rates are very high when treatment is discontinued, even after a single psychotic episode; a longer treatment period prior to discontinuation does not reduce the risk of relapse; many patients relapse soon after treatment reduction and discontinuation; transition from remission to relapse may be abrupt and with few or no early warning signs; once illness recurrence occurs symptoms rapidly return to levels similar to the initial psychotic episode; while most patients respond promptly to re-introduction of antipsychotic treatment after relapse, the response time is variable and notably, treatment failure appears to emerge in about 1 in 6 patients. These observations are consistent with contemporary thinking on the dopamine hypothesis, including the aberrant salience hypothesis. CONCLUSIONS: Given the difficulties in identifying those at risk of relapse, the ineffectiveness of rescue medications in preventing full-blown psychotic recurrence and the potentially serious consequences, adherence and other factors predisposing to relapse should be a major focus of attention in managing schizophrenia. The place of antipsychotic treatment discontinuation in clinical practice and in placebo-controlled clinical trials needs to be carefully reconsidered. BioMed Central 2013-02-08 /pmc/articles/PMC3599855/ /pubmed/23394123 http://dx.doi.org/10.1186/1471-244X-13-50 Text en Copyright ©2013 Emsley et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Emsley, Robin
Chiliza, Bonginkosi
Asmal, Laila
Harvey, Brian H
The nature of relapse in schizophrenia
title The nature of relapse in schizophrenia
title_full The nature of relapse in schizophrenia
title_fullStr The nature of relapse in schizophrenia
title_full_unstemmed The nature of relapse in schizophrenia
title_short The nature of relapse in schizophrenia
title_sort nature of relapse in schizophrenia
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3599855/
https://www.ncbi.nlm.nih.gov/pubmed/23394123
http://dx.doi.org/10.1186/1471-244X-13-50
work_keys_str_mv AT emsleyrobin thenatureofrelapseinschizophrenia
AT chilizabonginkosi thenatureofrelapseinschizophrenia
AT asmallaila thenatureofrelapseinschizophrenia
AT harveybrianh thenatureofrelapseinschizophrenia
AT emsleyrobin natureofrelapseinschizophrenia
AT chilizabonginkosi natureofrelapseinschizophrenia
AT asmallaila natureofrelapseinschizophrenia
AT harveybrianh natureofrelapseinschizophrenia